MPN-467 Findings From an Observational, Multicenter, Retrospective Analysis of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With Tagraxofusp in the European Expanded Access Program.
Fiche publication
Date publication
octobre 2022
Journal
Clinical lymphoma, myeloma & leukemia
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric
Tous les auteurs :
Herling M, Deconinck E, Anant M, Manteigas D, Riggi M, Mughal T, Angelucci E
Lien Pubmed
Résumé
Blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive hematologic malignancy with poor prognosis, is characterized by clonal expansion of plasmacytoid dendritic tumor cells expressing specific markers including the interleukin-3 receptor alpha (CD123). Tagraxofusp (TAG) is a CD123-targeted therapy approved by the FDA and EMA. A global expanded access program (EAP) was implemented prior to TAG's EMA authorization to provide access to patients in real-world practice.
Mots clés
BDPCN, CD123, MPN, myeloid malignancies, tagraxofusp, targeted therapy
Référence
Clin Lymphoma Myeloma Leuk. 2022 10;22 Suppl 2:S338